Status:
TERMINATED
Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX)
Lead Sponsor:
Centre Henri Becquerel
Collaborating Sponsors:
Ligue contre le cancer, France
Conditions:
Lymphoma
Heart Failure, Congestive
Eligibility:
All Genders
18-70 years
Brief Summary
Anthracycline-based chemotherapy is a key point of the treatment of patients with Hodgkin's and non-Hodgkin's lymphomas. However, cumulative doses are limited by cardiotoxicity, resulting in a marked ...
Eligibility Criteria
Inclusion
- Histologically proven lymphoma (Hodgkin's or non-Hodgkin's)
- Age \> 18 y/o and \< 70 y/o
- WHO score \< or = 2
- Life expectancy \> 6 mo
- Left ventricular ejection fraction \> 50%
- Informed consent
Exclusion
- Previous chemotherapy using anthracyclines
- History of radiation therapy
- History of congestive heart failure
- History of chronic renal insufficiency
- Contra indication to MR examination
- Atrial fibrillation and significant arrhythmia
- Pregnancy
Key Trial Info
Start Date :
January 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00195897
Start Date
January 1 2006
End Date
December 1 2009
Last Update
August 22 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Rouen
Rouen, France, 76031
2
Centre Henri Becquerel
Rouen, France, 76038